SG11202102068TA - Novel crispr enzymes and systems - Google Patents

Novel crispr enzymes and systems

Info

Publication number
SG11202102068TA
SG11202102068TA SG11202102068TA SG11202102068TA SG11202102068TA SG 11202102068T A SG11202102068T A SG 11202102068TA SG 11202102068T A SG11202102068T A SG 11202102068TA SG 11202102068T A SG11202102068T A SG 11202102068TA SG 11202102068T A SG11202102068T A SG 11202102068TA
Authority
SG
Singapore
Prior art keywords
systems
crispr enzymes
novel crispr
novel
enzymes
Prior art date
Application number
SG11202102068TA
Other languages
English (en)
Inventor
Feng Zhang
Ian Slaymaker
Soumya Kannan
Jonathan Gootenberg
Omar Abudayyeh
Original Assignee
Broad Inst Inc
Massachusetts Inst Technology
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Broad Inst Inc, Massachusetts Inst Technology, Harvard College filed Critical Broad Inst Inc
Publication of SG11202102068TA publication Critical patent/SG11202102068TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6823—Release of bound markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/128—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes processing or releasing ribozyme
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/155—Particles of a defined size, e.g. nanoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11202102068TA 2018-07-31 2019-07-31 Novel crispr enzymes and systems SG11202102068TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862712809P 2018-07-31 2018-07-31
US201862751421P 2018-10-26 2018-10-26
US201862775865P 2018-12-05 2018-12-05
US201962822639P 2019-03-22 2019-03-22
US201962873031P 2019-07-11 2019-07-11
PCT/US2019/044480 WO2020028555A2 (fr) 2018-07-31 2019-07-31 Nouvelles enzymes crispr et systèmes

Publications (1)

Publication Number Publication Date
SG11202102068TA true SG11202102068TA (en) 2021-03-30

Family

ID=67734806

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102068TA SG11202102068TA (en) 2018-07-31 2019-07-31 Novel crispr enzymes and systems

Country Status (9)

Country Link
US (1) US20220364071A1 (fr)
EP (1) EP3830256A2 (fr)
KR (1) KR20210053898A (fr)
CN (1) CN113348245A (fr)
AU (1) AU2019314433A1 (fr)
CA (1) CA3111432A1 (fr)
IL (1) IL281159A (fr)
SG (1) SG11202102068TA (fr)
WO (1) WO2020028555A2 (fr)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613852A3 (fr) 2011-07-22 2020-04-22 President and Fellows of Harvard College Évaluation et amélioration de la spécificité de clivage des nucléases
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9228207B2 (en) 2013-09-06 2016-01-05 President And Fellows Of Harvard College Switchable gRNAs comprising aptamers
AU2015298571B2 (en) 2014-07-30 2020-09-03 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
WO2018027078A1 (fr) 2016-08-03 2018-02-08 President And Fellows Of Harard College Éditeurs de nucléobases d'adénosine et utilisations associées
CA3033327A1 (fr) 2016-08-09 2018-02-15 President And Fellows Of Harvard College Proteines de fusion cas9-recombinase programmables et utilisations associees
WO2018039438A1 (fr) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation d'acides aminés non naturels dans des protéines au moyen de l'édition de bases
KR20240007715A (ko) 2016-10-14 2024-01-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵염기 에디터의 aav 전달
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
EP3592853A1 (fr) 2017-03-09 2020-01-15 President and Fellows of Harvard College Suppression de la douleur par édition de gène
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
SG11201908658TA (en) 2017-03-23 2019-10-30 Harvard College Nucleobase editors comprising nucleic acid programmable dna binding proteins
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
US11732274B2 (en) 2017-07-28 2023-08-22 President And Fellows Of Harvard College Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
US11970720B2 (en) 2017-08-22 2024-04-30 Salk Institute For Biological Studies RNA targeting methods and compositions
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
US20230053540A1 (en) 2019-02-19 2023-02-23 Massachusetts Institute Of Technology Treatment of liver injury
US20220154282A1 (en) 2019-03-12 2022-05-19 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
DE112020001342T5 (de) 2019-03-19 2022-01-13 President and Fellows of Harvard College Verfahren und Zusammensetzungen zum Editing von Nukleotidsequenzen
WO2020243661A1 (fr) 2019-05-31 2020-12-03 The Broad Institute, Inc. Méthodes de traitement de troubles métaboliques par ciblage de l'adcy5
CN116590257B (zh) * 2020-02-28 2024-04-30 辉大(上海)生物科技有限公司 VI-E型和VI-F型CRISPR-Cas系统及其用途
EP4118206A1 (fr) * 2020-03-11 2023-01-18 The Broad Institute Inc. Thérapeutiques editor basées sur la cible stat3 pour le traitement du mélanome et d'autres cancers
US20230346978A1 (en) * 2020-04-14 2023-11-02 University Of Massachusetts Dcas13-mediated therapeutic rna base editing for in vivo gene therapy
EP4146804A1 (fr) 2020-05-08 2023-03-15 The Broad Institute Inc. Méthodes et compositions d'édition simultanée des deux brins d'une séquence nucléotidique double brin cible
WO2022188039A1 (fr) 2021-03-09 2022-09-15 Huigene Therapeutics Co., Ltd. Système crispr/cas13 modifié et ses utilisations
WO2022068912A1 (fr) 2020-09-30 2022-04-07 Huigene Therapeutics Co., Ltd. Système crispr/cas13 modifié et ses utilisations
CN118109438A (zh) * 2020-09-30 2024-05-31 辉大(上海)生物科技有限公司 工程化的CRISPR/Cas13系统及其用途
WO2022136370A1 (fr) * 2020-12-22 2022-06-30 Helmholtz Zentrum Muenchen - Deutsches Forschungszentrum Für Gesundheit Und Umwelt (Gmbh) Application de crispr/cas13 pour la thérapie de maladies induites par un virus à arn et/ou une bactérie
CN115427561B (zh) * 2021-03-09 2024-06-04 辉大(上海)生物科技有限公司 工程化CRISPR/Cas13系统及其用途
EP4347818A2 (fr) 2021-06-01 2024-04-10 Arbor Biotechnologies, Inc. Systèmes d'édition de gènes comprenant une nucléase crispr et leurs utilisations
WO2022253351A1 (fr) * 2021-06-04 2022-12-08 中国科学院脑科学与智能技术卓越创新中心 Nouvelle protéine cas13, et procédé de criblage et utilisation de celle-ci
EP4141112A4 (fr) * 2021-07-08 2024-01-17 Korea Advanced Institute of Science and Technology Procédé de régulation ou d'édition d'expression d'arn par le biais de la régulation de l'activité de la protéine cas13
WO2023029532A1 (fr) * 2021-08-30 2023-03-09 Huigene Therapeutics Co., Ltd. Protéine cas6 modifiée et ses utilisations
WO2023051734A1 (fr) * 2021-09-29 2023-04-06 Huidagene Therapeutics Co., Ltd. Système crispr-cas13f modifié et ses utilisations
CN116083398B (zh) * 2021-11-05 2024-01-05 广州瑞风生物科技有限公司 分离的Cas13蛋白及其应用
CN114075572A (zh) * 2021-11-16 2022-02-22 珠海中科先进技术研究院有限公司 一种与门基因电路及获取该与门基因电路的方法
CN114085834A (zh) * 2021-11-16 2022-02-25 珠海中科先进技术研究院有限公司 一种癌细胞导向电路组及应用
CN116790555A (zh) * 2022-03-14 2023-09-22 上海鲸奇生物科技有限公司 Rna靶向基因编辑工具的开发
WO2023185878A1 (fr) * 2022-03-28 2023-10-05 Huidagene Therapeutics Co., Ltd. Système crispr-cas13f modifié et ses utilisations
WO2023184108A1 (fr) * 2022-03-28 2023-10-05 Huigene Therapeutics Co., Ltd. Système crispr-cas13 pour le traitement de maladies associées à ube3a
WO2023224352A1 (fr) * 2022-05-16 2023-11-23 주식회사 엔이에스바이오테크놀러지 Manipulation génique basée sur un complexe nanoparticule-crispr et son procédé de fabrication
WO2024043321A1 (fr) * 2022-08-24 2024-02-29 国立大学法人東京大学 Protéine et son utilisation
GB202214015D0 (en) * 2022-09-26 2022-11-09 Univ Oxford Innovation Ltd RNA editing vector
CN116083400B (zh) * 2022-12-08 2023-12-12 广州瑞风生物科技有限公司 Cas蛋白截短体、构建其的方法及其应用
CN117198390B (zh) * 2023-09-08 2024-03-12 中国科学院广州生物医药与健康研究院 通过设计和改造二硫键交联位点的slc膜蛋白复合物的制备方法
CN117230043B (zh) * 2023-11-14 2024-04-12 广州瑞风生物科技有限公司 Cas13蛋白及其应用
CN117904181A (zh) * 2024-01-26 2024-04-19 甘肃农业大学 陆地棉GhANN4基因在陆地棉抗旱和耐盐性中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US101A (en) 1836-12-06 Method of jcakibtg and furling iw sails fob ships
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US20040058886A1 (en) 2002-08-08 2004-03-25 Dharmacon, Inc. Short interfering RNAs having a hairpin structure containing a non-nucleotide loop
WO2008149176A1 (fr) 2007-06-06 2008-12-11 Cellectis Variants de méganucléase clivant une séquence cible d'adn issue du locus rosa26 de souris et leurs utilisations
EP2454371B1 (fr) 2009-07-13 2021-01-20 Somagenics, Inc. Modification chimique de petits arn en épingle à cheveux pour l'inhibition d'une expression de gène
CA2796600C (fr) 2010-04-26 2019-08-13 Sangamo Biosciences, Inc. Edition du genome d'un locus de rosa en utilisant des nucleases a doigt de zinc
JP2015527889A (ja) 2012-07-25 2015-09-24 ザ ブロード インスティテュート， インコーポレイテッド 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用
WO2014093709A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Procédés, modèles, systèmes et appareil pour identifier des séquences cibles pour les enzymes cas ou des systèmes crispr-cas pour des séquences cibles et transmettre les résultats associés
WO2014093701A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Génomique fonctionnelle employant des systèmes crispr-cas, des compositions, des procédés, des banques d'inactivation et leurs applications
US8993233B2 (en) 2012-12-12 2015-03-31 The Broad Institute Inc. Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
CN105658796B (zh) 2012-12-12 2021-10-26 布罗德研究所有限公司 用于序列操纵的crispr-cas组分系统、方法以及组合物
PT2898075E (pt) 2012-12-12 2016-06-16 Harvard College Manipulação e otimização de sistemas, métodos e composições de enzima melhorados para manipulação de sequências
WO2014093694A1 (fr) 2012-12-12 2014-06-19 The Broad Institute, Inc. Systèmes, procédés et compositions de crispr-nickase cas pour la manipulation de séquences dans les eucaryotes
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
US20140186843A1 (en) 2012-12-12 2014-07-03 Massachusetts Institute Of Technology Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof
PT2896697E (pt) 2012-12-12 2015-12-31 Massachusetts Inst Technology Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
MX2015007550A (es) 2012-12-12 2017-02-02 Broad Inst Inc Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas.
EP3553174A1 (fr) 2012-12-17 2019-10-16 President and Fellows of Harvard College Ingénierie de génome humain guidée par arn
US11332719B2 (en) 2013-03-15 2022-05-17 The Broad Institute, Inc. Recombinant virus and preparations thereof
US20140356956A1 (en) 2013-06-04 2014-12-04 President And Fellows Of Harvard College RNA-Guided Transcriptional Regulation
EP3011029B1 (fr) 2013-06-17 2019-12-11 The Broad Institute, Inc. Délivrance, fabrication et optimisation de systèmes, de procédés et de compositions pour la manipulation de séquences et applications thérapeutiques
WO2014204723A1 (fr) 2013-06-17 2014-12-24 The Broad Institute Inc. Modèles oncogènes basés sur la distribution et l'utilisation de systèmes crispr-cas, vecteurs et compositions
CA2915845A1 (fr) 2013-06-17 2014-12-24 The Broad Institute, Inc. Delivrance, modification et optimisation de systemes, procedes et compositions pour cibler et modeliser des maladies et des troubles lies aux cellules post-mitotiques
JP6702858B2 (ja) 2013-06-17 2020-06-03 ザ・ブロード・インスティテュート・インコーポレイテッド ウイルス成分を使用して障害および疾患をターゲティングするためのＣＲＩＳＰＲ−Ｃａｓ系および組成物の送達、使用および治療上の適用
EP3725885A1 (fr) 2013-06-17 2020-10-21 The Broad Institute, Inc. Génomique fonctionnelle utilisant des systèmes crispr-cas, compositions, procédés, cribles et applications de ces systèmes
EP4245853A3 (fr) 2013-06-17 2023-10-18 The Broad Institute, Inc. Systèmes, procédés et compositions à double nickase crispr-cas optimisés, pour la manipulation de séquences
AU2014281028B2 (en) 2013-06-17 2020-09-10 Massachusetts Institute Of Technology Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy
US10563225B2 (en) 2013-07-26 2020-02-18 President And Fellows Of Harvard College Genome engineering
US9068179B1 (en) * 2013-12-12 2015-06-30 President And Fellows Of Harvard College Methods for correcting presenilin point mutations
EP3294880A4 (fr) 2015-05-15 2018-12-26 Dharmacon, Inc. Arn de guidage unique synthétique pour l'édition de gène médiée par cas9
CN108513575A (zh) 2015-10-23 2018-09-07 哈佛大学的校长及成员们 核碱基编辑器及其用途
JP7267013B2 (ja) * 2016-06-17 2023-05-01 ザ・ブロード・インスティテュート・インコーポレイテッド Ｖｉ型ｃｒｉｓｐｒオルソログ及び系
CA3049961A1 (fr) * 2016-12-09 2018-06-14 The Broad Institute, Inc. Diagnostics bases sur un systeme effecteur crispr

Also Published As

Publication number Publication date
AU2019314433A1 (en) 2021-03-25
IL281159A (en) 2021-04-29
CA3111432A1 (fr) 2020-02-06
WO2020028555A2 (fr) 2020-02-06
WO2020028555A3 (fr) 2020-03-12
US20220364071A1 (en) 2022-11-17
CN113348245A (zh) 2021-09-03
EP3830256A2 (fr) 2021-06-09
KR20210053898A (ko) 2021-05-12

Similar Documents

Publication Publication Date Title
IL281159A (en) New CRISPR enzymes and systems
IL282746A (en) Enzyme and a new CRISPR/CAS12F system
EP3727469A4 (fr) Nouveaux systèmes et enzymes crispr
IL290678A (en) New crispr enzymes and systems
EP3500671A4 (fr) Systèmes et nouvelles enzymes crispr et systèmes
EP3500670A4 (fr) Nouveaux systèmes et enzymes crispr
SG10202010311SA (en) Novel Crispr Enzymes and Systems
IL291478A (en) New type vi crispr enzymes and their systems
LT3765615T (lt) Nauji tiksliniai crispr dnr fermentai ir sistemos
IL283169A (en) CRISPR-CAS12J enzyme and system
EP3655530A4 (fr) Nouveaux orthologues de crispr de type vi et systèmes associés
IL267541A (en) New fermentation systems and methods
IL284748A (en) Systems and methods against cyberbullying
EP3645728A4 (fr) Nouveaux orthologues de crispr de type vi et systèmes associés
EP3545085A4 (fr) Systèmes crispr/cpf1 et méthodes
EP3886737A4 (fr) Systèmes et procédés d'histotrypsie
EP3687422A4 (fr) Systèmes et procédés de décortication de l'articulation sacro-iliaque
IL281171A (en) Cellulose-synthase-like enzymes and uses thereof
GB201804807D0 (en) Interaactive systems and methods
EP3585511A4 (fr) Molybdène-métal et son procédé de fabrication
EP3692008A4 (fr) Procédés et systèmes de biocimentation
GB201909597D0 (en) Crispr type v-u1 system from mycobacterium mucogenicum and uses thereof
EP3589566A4 (fr) Systèmes et procédés pour transporteur
EP3903734A4 (fr) Convoyeur et système de convoyeur
EP3700521A4 (fr) Inhibiteurs d'adam9 et utilisations de ceux-ci